Trial Profile
A phase II study of Panitumumab combined with Irinotecan and S-1 as second line therapy in metastatic colorectal cancer patients with KRAS wild type
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 Jun 2016
Price :
$35
*
At a glance
- Drugs Panitumumab (Primary) ; Gimeracil/oteracil/tegafur; Irinotecan
- Indications Colorectal cancer
- Focus Therapeutic Use
- 16 Dec 2010 New trial record